---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001516"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:24:39.300086+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics enters ATM sales agreement for up to $1.2M with B. Riley Securities

## Summary
- Amendment No. 1 to At Market Issuance Sales Agreement with B. Riley Securities, dated Jan 9, 2025.
- Company may sell up to $1.2 million of common stock from time to time in at-the-market offerings.
- Agent commission is 3.0% of gross sales price; Company can terminate agreement on notice.
- Sales will be made under effective shelf registration statement (333-280244), declared effective Jan 8, 2025.

## SEC filing metadata
- accession: 0001493152-25-001516
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315225001516/0001493152-25-001516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315225001516/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001516
- JSON: https://secwatch.observer/filing/0001493152-25-001516.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001516.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.